An announcement from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.
Neuren Pharmaceuticals Limited reported a total comprehensive income of A$166.2 million for 2024, despite a decrease in revenue and profit from ordinary activities compared to 2023. The company experienced a significant impact on its financial statements due to a change in functional currency from Australian dollars to US dollars, which resulted in a foreign currency translation gain. Revenue was primarily driven by royalties and milestone payments under a licensing agreement with Acadia Pharmaceuticals, with notable contributions from the sale of a Rare Disease Priority Review Voucher. Research and development costs increased due to ongoing clinical trials, while corporate expenses decreased following previous bonuses related to regulatory milestones.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is known for its work on drugs like DAYBUE™ (trofinetide) and NNZ-2591, and it collaborates with partners such as Acadia Pharmaceuticals to advance its products.
YTD Price Performance: 10.82%
Average Trading Volume: 588
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $1.07B
Learn more about NEU stock on TipRanks’ Stock Analysis page.